News & Updates

Show Multimedia Only
Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated

Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

14 Sep 2026

Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality, with recurrent hospitalizations often marking a challenging phase in the patient journey. For patients, being discharged is not the end of their treatment journey. While discharge from the hospital represents an important milestone, long-term management is essential to reduce the risk of clinical deterioration and improve survival.1

Carvedilol, a beta-blocker recommended as part of guideline-directed treatment for heart failure. Guideline-directed medical therapy (GDMT) refers to the combination of evidence-based medicine recommended to improve outcomes for patients with HFrEF. Current treatment generally centers on four key pillars: an angiotensin receptor–neprilysin inhibitor (ARNi), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and a beta-blocker such as carvedilol. Together, these therapies work through different pathways to help reduce symptoms, slow disease progression, lower the risk of hospitalization, and improve survival.

Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

14 Sep 2026